Jefferies initiated coverage on SI-BONE with a new price target
$SIBN
Medical/Dental Instruments
Health Care
Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $27.00 → $19.00 | Buy | Needham |
| 3/28/2024 | $25.00 | Overweight | Piper Sandler |
| 10/12/2022 | $20.00 | Buy | Jefferies |
| 4/7/2022 | $34.00 | Overweight | Cantor Fitzgerald |
| 3/1/2022 | $30.00 → $28.00 | Overweight | Morgan Stanley |
| 1/18/2022 | $43.00 → $36.00 | Buy | B of A Securities |
| 12/21/2021 | $35.00 → $30.00 | Buy | Truist Securities |
| 11/9/2021 | $42.00 → $36.00 | Market Outperform | JMP Securities |
Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing growth of 22.8%Gross margin of 79.8%, representing an improvement of 80 basis pointsNet loss of $6.2 million, representing an improvement of 31.2%Positive adjusted EBITDA of $1.0 million$145.5 million in cash and equivalents, with $1.1 million net cash generated in the quarter Recent Operational Highlights (any comparisons are to the prior year period) 1,440 active U.S. physicians, representing growth of ~25%$2.1 million in trailing 12-month average revenue per territory, representing an increase
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/canaccord108/sibn/2510356. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be ar
SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/fnam2tia/. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for
SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SCHEDULE 13G - SI-BONE, Inc. (0001459839) (Subject)
10-Q - SI-BONE, Inc. (0001459839) (Filer)
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00
Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4/A - SI-BONE, Inc. (0001459839) (Issuer)
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa
Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing growth of 22.8%Gross margin of 79.8%, representing an improvement of 80 basis pointsNet loss of $6.2 million, representing an improvement of 31.2%Positive adjusted EBITDA of $1.0 million$145.5 million in cash and equivalents, with $1.1 million net cash generated in the quarter Recent Operational Highlights (any comparisons are to the prior year period) 1,440 active U.S. physicians, representing growth of ~25%$2.1 million in trailing 12-month average revenue per territory, representing an increase
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/canaccord108/sibn/2510356. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be ar
SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/fnam2tia/. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)